K-808
Primary Biliary Cholangitis
Kowa Research Institute, Inc.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Primary Biliary Cholangitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
URSODEOXYCHOLIC ACID Xijing Hospital of Digestive Diseases | Phase 4 | A |
Saroglitazar Zydus Therapeutics Inc. | Phase 3 | BB |
Fenofibrate Xijing Hospital of Digestive Diseases | Phase 3 | BB |
cs0159 Cascade Pharmaceuticals, Inc | Phase 3 | BB |
Obeticholic Acid Intercept Pharmaceuticals | Phase 3 | BB |
View all 50 →
Same molecule, other indications
K-808 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →